{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lin WW"],"funding":["Ministry of Education","Ministry of Science and Technology, Taiwan","Kaohsiung Medical University","National Health Research Institutes","Academia Sinica","Changhua Christian Hospital"],"pagination":["76"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7318374"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["27(1)"],"pubmed_abstract":["Monoclonal antibodies (mAbs) are a major targeted therapy for malignancies, infectious diseases, autoimmune diseases, transplant rejection and chronic inflammatory diseases due to their antigen specificity and longer half-life than conventional drugs. However, long-term systemic antigen neutralization by mAbs may cause severe adverse events. Improving the selectivity of mAbs to distinguish target antigens at the disease site from normal healthy tissue and reducing severe adverse events caused by the mechanisms-of-action of mAbs is still a pressing need. Development of pro-antibodies (pro-Abs) by installing a protease-cleavable Ab lock is a novel and advanced recombinant Ab-based strategy that efficiently masks the antigen binding ability of mAbs in the normal state and selectively \"turns o"],"journal":["Journal of biomedical science"],"pubmed_title":["Ab locks for improving the selectivity and safety of antibody drugs."],"pmcid":["PMC7318374"],"funding_grant_id":["108RSB0029","MOST107-2320-B-037-028-MY2","KMU-Q108001, KMU-Q109002, KMU-DK109004 and KMU-TC108A03","MOST 107-2320-B-037-024 -MY3 and MOST106-2311-B-037-001-MY2","KMU-DK108002, KMU-DK109001 and KMU-TC108A03","108-CCH-KMU-010","NHRI-EX107-10729EI and NHRI-EX108-10729EI","AS-107-TP-B11, AS-TP-107-L11 and AS-KPQ-106-TSPA","NK-108I08"],"pubmed_authors":["Cheng TL","Chuang CH","Lin WW","Lu YC"],"additional_accession":[]},"is_claimable":false,"name":"Ab locks for improving the selectivity and safety of antibody drugs.","description":"Monoclonal antibodies (mAbs) are a major targeted therapy for malignancies, infectious diseases, autoimmune diseases, transplant rejection and chronic inflammatory diseases due to their antigen specificity and longer half-life than conventional drugs. However, long-term systemic antigen neutralization by mAbs may cause severe adverse events. Improving the selectivity of mAbs to distinguish target antigens at the disease site from normal healthy tissue and reducing severe adverse events caused by the mechanisms-of-action of mAbs is still a pressing need. Development of pro-antibodies (pro-Abs) by installing a protease-cleavable Ab lock is a novel and advanced recombinant Ab-based strategy that efficiently masks the antigen binding ability of mAbs in the normal state and selectively \"turns o","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Jun","modification":"2025-04-05T13:42:09.003Z","creation":"2020-07-04T07:12:04Z"},"accession":"S-EPMC7318374","cross_references":{"pubmed":["32586313"],"doi":["10.1186/s12929-020-00652-z"]}}